Detalles de la búsqueda
1.
Immunogenicity and safety of porcine circovirus-free human rotavirus vaccine in healthy infants: a phase III, randomized trial.
J Infect Dis
; 2020 May 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32365189
2.
Assessment of an optimized manufacturing process for inactivated quadrivalent influenza vaccine: a phase III, randomized, double-blind, safety and immunogenicity study in children and adults.
BMC Infect Dis
; 18(1): 186, 2018 04 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-29669531
3.
Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children.
J Infect Dis
; 208(4): 544-53, 2013 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23847058
4.
Impact of maternal diphtheria-tetanus-acellular pertussis vaccination on pertussis booster immune responses in toddlers: Follow-up of a randomized trial.
Vaccine
; 39(11): 1598-1608, 2021 03 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33612341
5.
Hepatitis B response of premature infants after primary and booster immunisation with a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus/haemophilus influenzae type B vaccine.
Infect Dis Obstet Gynecol
; 2010: 802503, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-20396673
6.
Impact of tetanus-diphtheria-acellular pertussis immunization during pregnancy on subsequent infant immunization seroresponses: follow-up from a large randomized placebo-controlled trial.
Vaccine
; 38(8): 2105-2114, 2020 02 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-31776027
7.
Quadrivalent Influenza Vaccine Prevents Illness and Reduces Healthcare Utilization Across Diverse Geographic Regions During Five Influenza Seasons: A Randomized Clinical Trial.
Pediatr Infect Dis J
; 39(1): e1-e10, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31725115
8.
Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
Pediatr Infect Dis J
; 28(4 Suppl): S77-88, 2009 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-19325450
9.
Anamnestic Immune Response and Safety of an Inactivated Quadrivalent Influenza Vaccine in Primed Versus Vaccine-Naïve Children.
Pediatr Infect Dis J
; 38(2): 203-210, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30325891
10.
Clinical Presentation of Influenza in Children 6 to 35 Months of Age: Findings From a Randomized Clinical Trial of Inactivated Quadrivalent Influenza Vaccine.
Pediatr Infect Dis J
; 38(8): 866-872, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31306399
11.
Immunogenicity and reactogenicity of a booster dose of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age.
Pediatr Infect Dis J
; 27(7): 579-88, 2008 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-18536619
12.
Prevention of vaccine-matched and mismatched influenza in children aged 6-35 months: a multinational randomised trial across five influenza seasons.
Lancet Child Adolesc Health
; 2(5): 338-349, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30169267
13.
Antibody persistence and booster vaccination during the second and fifth years of life in a cohort of children who were born prematurely.
Pediatr Infect Dis J
; 26(9): 824-9, 2007 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-17721379
14.
Immunogenicity and reactogenicity of primary immunization with a novel combined Haemophilus influenzae Type b and Neisseria meningitidis Serogroup C-tetanus toxoid conjugate vaccine coadministered with a Diphtheria-tetanus-acellular Pertussis-hepatitis B-inactivated poliovirus vaccine at 2, 4 and 6 months.
Pediatr Infect Dis J
; 26(1): 1-7, 2007 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-17195697
15.
Antibody persistence after primary vaccination with a hexavalent DTPa-HBV-IPV/HiB vaccine coadministered with a meningococcal C-CRM197 vaccine and response to a DTPa-IPV/HiB booster at 18 months of age.
Pediatr Infect Dis J
; 25(10): 943-5, 2006 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-17006294
16.
Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine.
Pediatr Infect Dis J
; 25(8): 713-20, 2006 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-16874171
17.
The Impact of Childhood Acute Otitis Media on Parental Quality of Life in a Prospective Observational Cohort Study.
Clin Drug Investig
; 35(10): 613-24, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26350522
18.
Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies.
Hum Vaccin Immunother
; 11(10): 2359-69, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26176592
19.
Immunogenicity and reactogenicity of a three-dose primary vaccination course with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-haemophilus influenzae type b vaccine coadministered with a meningococcal C conjugate vaccine.
Pediatr Infect Dis J
; 23(12): 1109-15, 2004 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-15626947
20.
Five-year antibody persistence and safety following a booster dose of combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine.
Pediatr Infect Dis J
; 31(10): 1074-7, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22828645